A Phase 1/2 interventional study of Stereotactic body radiotherapy and Nivolumab in Non-small Cell Lung Cancer Stage II and Non-small Cell Lung Cancer Stage I, sponsored by Royal Marsden NHS Foundation Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.
Sponsored by Royal Marsden NHS Foundation Trust · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 43 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 74th largest by enrollment, is one of 15 that started in 2018, is one of 12 in phase 1/2, and was the 56th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Liza Villaruz, MD · Sites in United States
Ages 18+
Diwakar Davar · Sites in United States
Ages 18+
EuroCityClinic LLC · Sites in Russia
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 78 · Phase 3 24 · Phase 4 2
First in 2006; this study’s year is marked. 15 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 62 across 6,028 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 66 across the 120 interventional studies. Of the 63 that completed or were terminated, 44 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 120 have an industry lead sponsor. The 10 most frequent:
Royal Marsden NHS Foundation Trust is the lead sponsor of 275 studies on the registry; 54 are open to participants now.
11 studies in Carcinoma, Non-Small-Cell Lung by Royal Marsden NHS Foundation Trust: 3 open now, 4 under way, none of them phase 3. Of 2 finished, 2 (100%) have results posted.
Among the 11 studies in Carcinoma, Non-Small-Cell Lung by Royal Marsden NHS Foundation Trust, this one is one of 2 that started in 2018, is one of 2 in phase 1/2, and was the 6th registered.
Royal Marsden NHS Foundation Trust’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1998.
13 of the studies testing nivolumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02595944Phase 3National Cancer Institute (NCI)Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) | 2027-05-31 |
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
| NCT05597800Universita di VeronaNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | 2026-12-31 |
| NCT06946797Bristol-Myers SquibbA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | 2027-02-05 |
| NCT06275360VA Office of Research and DevelopmentRepositioning Immunotherapy in VetArans With Lung Cancer | 2027-02-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Royal Marsden NHS Foundation Trust’s 11 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is a single arm, multi-centre, phase II open label study of nivolumab with stereotactic body radiotherapy (SBRT) for early stage non-small cell lung cancer.
SBRT will be delivered in either 3 or 5 fractions for peripheral disease or 8 fractions in central disease. A flat dose of 240 mg nivolumab infusion will begin after the final fraction of SBRT, within 24 hours and typically on the same day. Nivolumab will subsequently be given every 2 weeks at a flat dose of 240 mg for a further 13 cycles followed by Nivolumab 480mg Q4W for 7 cycles until 20 cycles in total are complete, unless any study drug discontinuation criteria are met. Treatment (20 cycles) will take a minimum of 1 year to complete but may exceed this timeframe if treatment delays are encountered.
(Patients who have enrolled on Nivolumab Q2W 240mg regimen for 26 cycles and are beyond cycle 14 will receive 26 cycles Q2W in total to complete treatment).
Assessment of toxicities will be performed at each clinic visit during treatment, at 30 days after the final nivolumab infusion and until 100 days after the final nivolumab infusion. Changes in spirometry values and PFTs will be assessed throughout the trial.
Relapse rates will be assessed with staging CT scans at 3, 6, 12, 18 and 24 months post SBRT.
An exploratory assessment will be made of the effect pre-treatment pulmonary function tests (PFTs) have on outcome measures.
This is a single arm, multi-centre, phase II open label study of nivolumab with stereotactic body radiotherapy (SBRT) for early stage non-small cell lung cancer.
Current United Kingdom (UK) guidelines for SBRT do not specify exclusion pulmonary function criteria. Severely reduced Forced Expiratory Volume in 1 second (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO) (\<40% predicted) are common reasons for medical inoperability leading to the choice of SBRT. In a large prospective study of patients undergoing SBRT, poor baseline PFT was not predictive of toxicity including pneumonitis. At the 2 year follow up, the mean decline in percentage of predicted forced expiratory volume in one second (FEV1) and diffusion capacity of carbon monoxide (DLCO) were only 5.8% and 6.3% respectively. Focal SBRT is a well-tolerated procedure and acute complications are generally transient. Symptomatic radiation pneumonitis has been reported at rates of 4-25% of patients.
Drug induced pneumonitis is reported at 6% in lung cancer patients receiving nivolumab and at 2% with grade 3-4 toxicity. Of note, such rates are similar or lower to other drugs used in NSCLC including docetaxel for which no PFT restrictions occur. In this study, frequent assessment of spirometry values may help to predict patients that are developing subclinical pneumonitis and prompt for early intervention.
SBRT will be delivered in either 3 or 5 fractions for peripheral disease or 8 fractions in central disease. A flat dose of 240 mg nivolumab infusion will begin after the final fraction of SBRT, within 24 hours and typically on the same day. Nivolumab will subsequently be given every 2 weeks at a flat dose of 240 mg for a further 13 cycles followed by Nivolumab 480mg Q4W for 7 cycles until 20 cycles in total are complete, unless any study drug discontinuation criteria are met. The study will recruit 31 patients. We anticipate it will take approximately 18 months to recruit 31 patients.
The study will include subjects with histologically verified NSCLC deemed by a local multidisciplinary team (MDT) to have anatomical stage T1-3 [≤6cm] N0 M0 by means of computed tomography (CT) and fludeoxyglucose-positron emission tomography (FDG-PET) , amenable to radical treatment with SBRT and inoperable due to medical co-morbidity, being technically unresectable or patient declining surgery after offer of surgical assessment.
Subjects will receive nivolumab as per the treatment schedule unless any withdrawal criteria are met. The first nivolumab infusion will be given after the final fraction of SBRT, within 24 hours and generally on the same day. Clinical follow up and investigations are as detailed in the schedule of assessment.
The first 5 patients to enroll must have Eastern Co-operative Oncology Group (ECOG) performance status (PS) \< 2 at the time of first dose of investigational medical product (IMP). An Independent Data Monitoring Committee (IDMC) will meet when the first 5 patients have reached 3 months follow up from their 1st dose of nivolumab or have withdrawn consent to follow-up. Patients that have enrolled but did not receive IMP will be replaced. The IDMC, if satisfied with the safety data from the initial 5 patients, may recommend escalation to include recruitment of patients with ECOG performance status of 2. Further patients of PS \<2 may enroll while awaiting the outcome of the IDMC meeting.
The IDMC will perform a further safety review when the first 5 patients enrolled with ECOG performance status 2 have reached 3 months follow up from their final fraction of radiotherapy or have withdrawn consent to follow-up. Patients that have enrolled but did not receive IMP will be replaced. Further patients with ECOG performance status 2 will not be able to enroll unless recommendation is given by the IDMC. In the event that 5 PS 2 patients have not enrolled by the point that the 15th recruited patient has reached 3 months follow up, then there will be a further mandated IDMC meeting to assess safety data from the study. Patients may continue to enroll while awaiting the outcome of this IDMC meeting.
Assessment of toxicities will be performed at each clinic visit during treatment, at 30 days after the final nivolumab infusion and until 100 days after the final nivolumab infusion. Changes in spirometry values and PFTs will be assessed throughout the trial.
Relapse rates will be assessed with staging CT scans at 3, 6, 12, 18 and 24 months post SBRT.
An exploratory assessment will be made of the effect pre-treatment pulmonary function tests (PFTs) have on outcome measures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Screening laboratory values must meet the following criteria prior to commencement of treatment:
i) WBCs ≥ 2000/μL ii) Neutrophils ≥1500/μL iii) ≥ 100 X10³/μL iv) ≥ 9.0 g/dL v) Serum creatinine of ≤ 1.5 X or (CrCl)/ (GFR) > 40 mL/minute (using Cockcroft/Gault formula or as assessed by local practice)
Exclusion Criteria:
Positive test for virus (HBV) using HBV surface antigen (HBVsAg) test or positive test for virus (HCV) using HCV ribonucleic acid (RNA) or HCV antibody test indicating acute or chronic infection
o Patients with a positive HCV antibody but no detection of HCV RNA indicating no current infection are eligible
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a single arm study of nivolumab administered on completion of stereotactic body radiotherapy (SBRT) to patients with early stage NSCLC. The first 5 patients to enroll must have Eastern Co-operative Oncology Group (ECOG) performance status \< 2 at the time of first dose of investigational medical product (IMP). An Independent Data Monitoring Committee (IDMC) will meet when the first 5 patients have reached 3 months follow up from their 1st dose of nivolumab or have withdrawn consent to follow-up. The IDMC, if satisfied with the safety data from the initial 5 patients, may recommend escalation to include recruitment of patients with ECOG performance status of 2.
Radiation: Stereotactic body radiotherapy · Drug: Nivolumab
Patients will receive a total of 54 Gy if delivered in 3 fractions, 55 Gy if delivered in 5 fractions or 60 Gy if delivered in 8 fractions.
Also known as: SBRT
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody, that binds to the PD-1 receptor and blocks interaction with its ligands PD-L1 and PD-L2. Nivolumab will be administered intravenously at a flat dose of 240 mg q2w over 30 minutes for 13 cycles followed by 480mg q4w over 60 minutes for 7 cycles, until 20 cycles in total to complete (a minimum of 1 year of treatment if no delays are encountered).
Also known as: L01XC17, Opdivo
Assessment of Lung Toxicity (Pneumonitis) From Treatment With Nivolumab After SBRT for Early Stage NSCLC
Number of participants with grade ≥ 3 pneumonitis from treatment with nivolumab after stereotactic body radiotherapy (SBRT) within 6 months of the final fraction of SBRT (2-3 weeks treatment duration depending on dosing). A rate that exceeds 20% will be deemed unacceptable and will lead to a rejection of the null hypothesis.
Time frame: Six months from final dose of SBRT (2-3 weeks) administered for each patient
Adverse Events (Toxicity) by Worst Grade
Rates of toxicity will be summarised as worst toxicity grade during treatment as per CTCAE v. 4 after treatment with Nivolumab following SBRT.
Time frame: 24 months from last dose of SBRT (2-3 weeks treatment duration)
Proportion of Patient Receiving 1,2,3,4,5 and 6 Doses of Nivolumab Within 16 Weeks of Commencing Adjuvant Nivolumab After SBRT for Early Stage NSCLC
The proportion of patients receiving 1,2,3,4,5 and 6 doses within 16 weeks of commencing treatment are reported with a 95% exact confidence interval.
Time frame: Within 16 weeks of each patient commencing treatment with Nivolumab after SBRT (2-3 weeks duration)
Disease Relapse - To Assess Local, Local-regional and Distant Disease Relapse Rates
All rates of relapse (local, loco-regional and distant rates) were evaluated using the 30 patients in the efficacy population and presented as a proportion with a 95% exact binomial confidence interval. Time to event analysis was not performed within these endpoints as the number of events were too low.
Time frame: 24 months from last dose of SBRT (2-3 weeks duration)
Overall Survival
Overall survival (OS) was evaluated for 29 out of the 31 patients in the efficacy population (1 patient withdrew during SBRT and no SBRT start date was recorded) OS rates at 12 and 24 months are reported.
Time frame: Overall survival rate (OS) at 12 and 24 months
Disease Free Survival
Disease-free survival (DFS) was evaluated for 29 out of the 31 patients in the efficacy population (1 patient withdrew during SBRT and no SBRT start date was recorded) DFS rates at 6, 12 and 24 months are reported.
Time frame: Disease Free Survival (DFS) at 6, 12 and 24 months
Health-related Quality of Life (HRQoL) Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) in Patients Treated With Nivolumab After SBRT for Early Stage NSCLC
Estimation of the health-related quality of life (HRQoL) score at each time point of analysis (screening, then at 3, 6, 9, 12, 18, 24 months post-SBRT). QOL questionnaires will be scored according to the EORTC Quality of Life Questionnaire (QLQ-C30) version 3 scoring manual. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level, in cases of a functioning scale a better outcome, but for symptom scales a higher score represents a worse outcome.
Time frame: 24 months from last dose of SBRT (2-3 weeks duration)
HRQoL Using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) in Patients Treated With Nivolumab After SBRT for Early Stage NSCLC.
Estimation of HRQoL in patients treated with Nivolumab after SBRT for early stage NSCLC using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at each time point of analysis (screening, then at 3, 6, 9, 12, 18, 24 months post-SBRT). QOL data will be scored according to the QLQ-LC13 scoring manual, which includes one multi-item scale to assess dyspnea, and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and haemoptysis, all had a score ranging from 0 to 100, where a higher score represents a high level of symptomatology/problems.
Time frame: 24 months from last dose of SBRT (2-3 weeks)
Thirty-six patients were registered into the study from the Royal Marsden site between February 2018 and January 2024. However, only 31 were eligible and of which 29 started study treatment.
| Milestone | Arm 1 Tolerability |
|---|---|
| Started | 31 |
| Received sbrt treatment | 30 |
| Received nivolumab treatment (primary analysis population) | 29 |
| Completed study treatment | 6 |
| Completed | 20 |
| Not completed | 11 |
| Withdrew: Death | 4 |
| Withdrew: Deterioration in health | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Lost to follow-up | 4 |
Number of participants with grade ≥ 3 pneumonitis from treatment with nivolumab after stereotactic body radiotherapy (SBRT) within 6 months of the final fraction of SBRT (2-3 weeks treatment duration depending on dosing). A rate that exceeds 20% will be deemed unacceptable and will lead to a rejection of the null hypothesis.
| Participants | Arm 1 Tolerabilty |
|---|---|
| Assessment of Lung Toxicity (Pneumonitis) From Treatment With Nivolumab After SBRT for Early Stage NSCLC | 0 |
Rates of toxicity will be summarised as worst toxicity grade during treatment as per CTCAE v. 4 after treatment with Nivolumab following SBRT.
| Participants | Arm 1 Tolerabilty |
|---|---|
| Grade 1 | 1 |
| Grade 2 | 11 |
| Grade 3 | 16 |
| Grade 4 | 1 |
The proportion of patients receiving 1,2,3,4,5 and 6 doses within 16 weeks of commencing treatment are reported with a 95% exact confidence interval.
| proportion of participants | Arm 1 Tolerabilty |
|---|---|
| Received 1 dose | 1.00 (0.88 to 1.00) |
| Received 2 doses | 0.90 (0.73 to 0.98) |
| Received 3 doses | 0.83 (0.64 to 0.94) |
| Received 4 doses | 0.79 (0.60 to 0.92) |
| Received 5 doses | 0.79 (0.60 to 0.92) |
| Received 6 doses | 0.76 (0.56 to 0.90) |
All rates of relapse (local, loco-regional and distant rates) were evaluated using the 30 patients in the efficacy population and presented as a proportion with a 95% exact binomial confidence interval. Time to event analysis was not performed within these endpoints as the number of events were too low.
| Proportion of participants | Arm 1 Tolerabilty |
|---|---|
| Local relapse | 0.03 (0.001 to 0.17) |
| Loco-regional relapse | 0.03 (0.001 to 0.17) |
| Distant relapse | 0.07 (0.01 to 0.22) |
| Any relapse | 0.13 (0.04 to 0.31) |
Overall survival (OS) was evaluated for 29 out of the 31 patients in the efficacy population (1 patient withdrew during SBRT and no SBRT start date was recorded) OS rates at 12 and 24 months are reported.
| Percentage of participants | Arm 1 Tolerabilty |
|---|---|
| 12 month OS rate | 100 (NA to NA) |
| 24 month OS rate | 89 (70 to 96) |
Disease-free survival (DFS) was evaluated for 29 out of the 31 patients in the efficacy population (1 patient withdrew during SBRT and no SBRT start date was recorded) DFS rates at 6, 12 and 24 months are reported.
| percentage of participants | Arm 1 Tolerabilty |
|---|---|
| 6 month DFS | 97 (78 to 99) |
| 12 month DFS | 93 (75 to 98) |
| 24 month DFS | 85 (65 to 94) |
Estimation of the health-related quality of life (HRQoL) score at each time point of analysis (screening, then at 3, 6, 9, 12, 18, 24 months post-SBRT). QOL questionnaires will be scored according to the EORTC Quality of Life Questionnaire (QLQ-C30) version 3 scoring manual. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level, in cases of a functioning scale a better outcome, but for symptom scales a higher score represents a worse outcome.
| score on a scale | Arm 1 Tolerabilty |
|---|---|
| EORTC QLQ-C30 Global Health Status: Screening | 67 (33 to 100) |
| EORTC QLQ-C30 Global Health Status: 3 months PSBRT | 67 (25 to 100) |
| EORTC QLQ-C30 Global Health Status: 6 months PSBRT | 63 (0 to 100) |
| EORTC QLQ-C30 Global Health Status: 9 months PSBRT | 67 (0 to 100) |
| EORTC QLQ-C30 Global Health Status: 12 months PSBRT | 67 (17 to 100) |
| EORTC QLQ-C30 Global Health Status: 15 months PSBRT | 67 (25 to 100) |
| EORTC QLQ-C30 Global Health Status: 18 months PSBRT | 58 (17 to 100) |
| EORTC QLQ-C30 Global Health Status: 24 months PSBRT | 67 (17 to 100) |
| EORTC QLQ-C30 Physical functioning: Screening | 80 (53 to 100) |
| EORTC QLQ-C30 Physical functioning: 3 month PSBRT | 80 (40 to 100) |
| EORTC QLQ-C30 Physical functioning: 6 month PSBRT | 73 (13 to 100) |
| EORTC QLQ-C30 Physical functioning: 9 month PSBRT | 67 (13 to 100) |
| EORTC QLQ-C30 Physical functioning: 12 month PSBRT | 70 (13 to 100) |
| EORTC QLQ-C30 Physical functioning: 15 month PSBRT | 53 (27 to 100) |
| EORTC QLQ-C30 Physical functioning: 18 month PSBRT | 80 (7 to 100) |
| EORTC QLQ-C30 Physical functioning: 24 month PSBRT | 73 (13 to 100) |
| EORTC QLQ-C30 Role functioning: Screening | 83 (0 to 100) |
| EORTC QLQ-C30 Role functioning: 3 months PSBRT | 83 (33 to 100) |
| EORTC QLQ-C30 Role functioning: 6 months PSBRT | 67 (0 to 100) |
| EORTC QLQ-C30 Role functioning: 9 months PSBRT | 83 (17 to 100) |
| EORTC QLQ-C30 Role functioning: 12 months PSBRT | 67 (0 to 100) |
| EORTC QLQ-C30 Role functioning: 15 months PSBRT | 67 (0 to 100) |
| EORTC QLQ-C30 Role functioning: 18 months PSBRT | 67 (0 to 100) |
| EORTC QLQ-C30 Role functioning: 24 months PSBRT | 20 (0 to 100) |
| EORTC QLQ-C30 Emotional functioning: Screening | 92 (33 to 100) |
| EORTC QLQ-C30 Emotional functioning: 3 month PSBRT | 92 (25 to 100) |
| EORTC QLQ-C30 Emotional functioning: 6 month PSBRT | 83 (0 to 100) |
| EORTC QLQ-C30 Emotional functioning: 9 month PSBRT | 83 (42 to 100) |
| EORTC QLQ-C30 Emotional functioning: 12 month PSBRT | 75 (0 to 100) |
| EORTC QLQ-C30 Emotional functioning: 15 month PSBRT | 75 (0 to 100) |
| EORTC QLQ-C30 Emotional functioning: 18 month PSBRT | 75 (17 to 100) |
| EORTC QLQ-C30 Emotional functioning: 24 month PSBRT | 75 (8 to 100) |
| EORTC QLQ-C30 Cognitive functioning: Screening | 83 (50 to 100) |
| EORTC QLQ-C30 Cognitive functioning: 3 month PSBRT | 92 (33 to 100) |
| EORTC QLQ-C30 Cognitive functioning: 6 month PSBRT | 83 (0 to 100) |
| EORTC QLQ-C30 Cognitive functioning: 9 month PSBRT | 83 (33 to 100) |
| EORTC QLQ-C30 Cognitive functioning: 12 month PSBRT | 83 (17 to 100) |
| EORTC QLQ-C30 Cognitive functioning: 15 month PSBRT | 83 (0 to 100) |
| EORTC QLQ-C30 Cognitive functioning: 18 month PSBRT | 75 (17 to 100) |
| EORTC QLQ-C30 Cognitive functioning: 24 month PSBRT | 67 (17 to 100) |
| EORTC QLQ-C30 Social functioning: Screening | 92 (33 to 100) |
| EORTC QLQ-C30 Social functioning: 3 month PSBRT | 83 (0 to 100) |
| EORTC QLQ-C30 Social functioning: 6 month PSBRT | 75 (33 to 100) |
| EORTC QLQ-C30 Social functioning: 9 month PSBRT | 83 (17 to 100) |
| EORTC QLQ-C30 Social functioning: 12 month PSBRT | 67 (0 to 100) |
| EORTC QLQ-C30 Social functioning: 15 month PSBRT | 83 (0 to 100) |
| EORTC QLQ-C30 Social functioning: 18 month PSBRT | 67 (17 to 100) |
| EORTC QLQ-C30 Social functioning: 24 month PSBRT | 67 (0 to 100) |
| EORTC QLQ-C30 Fatigue: Screening | 22 (0 to 56) |
| EORTC QLQ-C30 Fatigue: 3 month PSBRT | 22 (0 to 78) |
| EORTC QLQ-C30 Fatigue: 6 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-C30 Fatigue: 9 month PSBRT | 22 (0 to 89) |
| EORTC QLQ-C30 Fatigue: 12 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-C30 Fatigue: 15 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-C30 Fatigue: 18 month PSBRT | 33 (0 to 67) |
| EORTC QLQ-C30 Fatigue: 24 month PSBRT | 44 (0 to 78) |
| EORTC QLQ-C30 Nausea and vomiting: Screening | 0 (0 to 17) |
| EORTC QLQ-C30 Nausea and vomiting: 3 month PSBRT | 0 (0 to 33) |
| EORTC QLQ-C30 Nausea and vomiting: 6 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-C30 Nausea and vomiting: 9 month PSBRT | 0 (0 to 17) |
| EORTC QLQ-C30 Nausea and vomiting: 12 month PSBRT | 0 (0 to 50) |
| EORTC QLQ-C30 Nausea and vomiting: 15 month PSBRT | 0 (0 to 50) |
| EORTC QLQ-C30 Nausea and vomiting: 18 month PSBRT | 0 (0 to 33) |
| EORTC QLQ-C30 Nausea and vomiting: 24 month PSBRT | 0 (0 to 33) |
| EORTC QLQ-C30 Pain: Screening | 0 (0 to 67) |
| EORTC QLQ-C30 Pain: 3 month PSBRT | 0 (0 to 83) |
| EORTC QLQ-C30 Pain: 6 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Pain: 9 month PSBRT | 17 (0 to 100) |
| EORTC QLQ-C30 Pain: 12 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-C30 Pain: 15 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Pain: 18 month PSBRT | 17 (0 to 83) |
| EORTC QLQ-C30 Pain: 24 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Dyspnea: Screening | 33 (0 to 100) |
| EORTC QLQ-C30 Dyspnea: 3 month PSBRT | 33 (0 to 33) |
| EORTC QLQ-C30 Dyspnea: 6 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-C30 Dyspnea: 9 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-C30 Dyspnea: 12 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-C30 Dyspnea: 15 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-C30 Dyspnea: 18 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-C30 Dyspnea: 24 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-C30 Insomnia: Screening | 0 (0 to 100) |
| EORTC QLQ-C30 Insomnia: 3 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Insomnia: 6 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-C30 Insomnia: 9 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-C30 Insomnia: 12 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-C30 Insomnia: 15 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-C30 Insomnia: 18 month PSBRT | 17 (0 to 67) |
| EORTC QLQ-C30 Insomnia: 24 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-C30 Appetite Loss: Screening | 0 (0 to 67) |
| EORTC QLQ-C30 Appetite Loss: 3 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-C30 Appetite Loss: 6 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-C30 Appetite Loss: 9 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Appetite Loss: 12 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Appetite Loss: 15 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-C30 Appetite Loss: 18 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-C30 Appetite Loss: 24 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-C30 Constipation: Screening | 0 (0 to 67) |
| EORTC QLQ-C30 Constipation: 3 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Constipation: 6 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Constipation: 9 month PSBRT | 0 (0 to 33) |
| EORTC QLQ-C30 Constipation: 12 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-C30 Constipation: 15 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Constipation: 18 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Constipation: 24 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-C30 Diarrhea: Screening | 0 (0 to 33) |
| EORTC QLQ-C30 Diarrhea: 3 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-C30 Diarrhea: 6 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Diarrhea: 9 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-C30 Diarrhea: 12 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-C30 Diarrhea: 15 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Diarrhea: 18 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-C30 Diarrhea: 24 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Financial Difficulties: Screening | 0 (0 to 67) |
| EORTC QLQ-C30 Financial Difficulties: 3 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Financial Difficulties: 6 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Financial Difficulties: 9 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Financial Difficulties: 12 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Financial Difficulties: 15 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Financial Difficulties: 18 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-C30 Financial Difficulties: 24 month PSBRT | 0 (0 to 67) |
Estimation of HRQoL in patients treated with Nivolumab after SBRT for early stage NSCLC using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at each time point of analysis (screening, then at 3, 6, 9, 12, 18, 24 months post-SBRT). QOL data will be scored according to the QLQ-LC13 scoring manual, which includes one multi-item scale to assess dyspnea, and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and haemoptysis, all had a score ranging from 0 to 100, where a higher score represents a high level of symptomatology/problems.
| score on a scale | Arm 1 Tolerabilty |
|---|---|
| EORTC QLQ-LC13 Dyspnea: Screening | 22 (0 to 56) |
| EORTC QLQ-LC13 Dyspnea: 3 month PSBRT | 22 (0 to 89) |
| EORTC QLQ-LC13 Dyspnea: 6 month PSBRT | 22 (0 to 100) |
| EORTC QLQ-LC13 Dyspnea: 9 month PSBRT | 33 (0 to 67) |
| EORTC QLQ-LC13 Dyspnea: 12 month PSBRT | 33 (0 to 89) |
| EORTC QLQ-LC13 Dyspnea: 15 month PSBRT | 22 (0 to 89) |
| EORTC QLQ-LC13 Dyspnea: 18 month PSBRT | 33 (0 to 67) |
| EORTC QLQ-LC13 Dyspnea: 24 month PSBRT | 33 (0 to 78) |
| EORTC QLQ-LC13 Coughing: Screening | 33 (0 to 67) |
| EORTC QLQ-LC13 Coughing: 3 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-LC13 Coughing: 6 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-LC13 Coughing: 9 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-LC13 Coughing: 12 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-LC13 Coughing: 15 month PSBRT | 33 (0 to 67) |
| EORTC QLQ-LC13 Coughing: 18 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-LC13 Coughing: 24 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Haemoptysis: Screening | 0 (0 to 100) |
| EORTC QLQ-LC13 Haemoptysis: 3 month PSBRT | 0 (0 to 33) |
| EORTC QLQ-LC13 Haemoptysis: 6 month PSBRT | 0 (0 to 33) |
| EORTC QLQ-LC13 Haemoptysis: 9 month PSBRT | 0 (0 to 0) |
| EORTC QLQ-LC13 Haemoptysis: 12 month PSBRT | 0 (0 to 33) |
| EORTC QLQ-LC13 Haemoptysis: 15 month PSBRT | 0 (0 to 0) |
| EORTC QLQ-LC13 Haemoptysis: 18 month PSBRT | 0 (0 to 0) |
| EORTC QLQ-LC13 Haemoptysis: 24 month PSBRT | 0 (0 to 33) |
| EORTC QLQ-LC13 Sore mouth: Screening | 0 (0 to 33) |
| EORTC QLQ-LC13 Sore mouth: 3 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Sore mouth: 6 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Sore mouth: 9 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Sore mouth: 12 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Sore mouth: 15 month PSBRT | 0 (0 to 0) |
| EORTC QLQ-LC13 Sore mouth: 18 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Sore mouth: 24 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Dysphagia: Screening | 0 (0 to 33) |
| EORTC QLQ-LC13 Dysphagia: 3 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Dysphagia: 6 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Dysphagia: 9 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Dysphagia: 12 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Dysphagia: 15 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Dysphagia: 18 month PSBRT | 0 (0 to 33) |
| EORTC QLQ-LC13 Dysphagia: 24 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Peripheral neuropathy: Screening | 0 (0 to 67) |
| EORTC QLQ-LC13 Peripheral neuropathy: 3 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Peripheral neuropathy: 6 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Peripheral neuropathy: 9 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Peripheral neuropathy: 12 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Peripheral neuropathy: 15 month PSBRT | 17 (0 to 67) |
| EORTC QLQ-LC13 Peripheral neuropathy: 18 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Peripheral neuropathy: 24 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Alopecia: Screening | 0 (0 to 100) |
| EORTC QLQ-LC13 Alopecia: 3 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Alopecia: 6 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Alopecia: 9 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Alopecia: 12 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Alopecia: 15 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Alopecia: 18 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Alopecia: 24 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Pain in the chest: Screening | 0 (0 to 67) |
| EORTC QLQ-LC13 Pain in the chest: 3 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Pain in the chest: 6 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Pain in the chest: 9 month PSBRT | 0 (0 to 33) |
| EORTC QLQ-LC13 Pain in the chest: 12 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Pain in the chest: 15 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Pain in the chest: 18 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Pain in the chest: 24 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Pain in the arm/shoulder: Screening | 0 (0 to 100) |
| EORTC QLQ-LC13 Pain in the arm/shoulder: 3 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Pain in the arm/shoulder: 6 month PSBRT | 0 (0 to 33) |
| EORTC QLQ-LC13 Pain in the arm/shoulder: 9 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Pain in the arm/shoulder: 12 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Pain in the arm/shoulder: 15 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Pain in the arm/shoulder: 18 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Pain in the arm/shoulder: 24 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Pain in other areas: Screening | 0 (0 to 100) |
| EORTC QLQ-LC13 Pain in other areas: 3 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Pain in other areas: 6 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Pain in other areas: 9 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Pain in other areas: 12 month PSBRT | 33 (0 to 100) |
| EORTC QLQ-LC13 Pain in other areas: 15 month PSBRT | 0 (0 to 67) |
| EORTC QLQ-LC13 Pain in other areas: 18 month PSBRT | 0 (0 to 100) |
| EORTC QLQ-LC13 Pain in other areas: 24 month PSBRT | 0 (0 to 100) |
Collected over AEs will be recorded from consent until 100 days post the final infusion of nivolumab (average 12 cycles, typically 24 weeks, maximum 22 cycles/44 weeks). They will be systematically assessed at screening, each cycle of treatment (14 days), a safety follow-up visit (14 days after final infusion of nivolumab), and at each follow-up visit (3 month-, 6 month-, 9 month-, 12 month, 15 month-, 18 month- and 24 month-post SBRT) until participants reach the 100 days post the final infusion of nivolumab.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 Tolerabilty | 6/31 (19.4%) | 18/31 (58.1%) | 30/31 (96.8%) |
| Event | Arm 1 Tolerabilty |
|---|---|
| Lung infectionInfections and infestations | 4/31 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 3/31 |
| AnemiaBlood and lymphatic system disorders | 1/31 |
| Chest painCardiac disorders | 1/31 |
| Heart failureCardiac disorders | 1/31 |
| Myocardial infarctionCardiac disorders | 1/31 |
| Adrenal insufficiencyEndocrine disorders | 1/31 |
| Abdominal painGastrointestinal disorders | 1/31 |
| ColitisGastrointestinal disorders | 1/31 |
| DiarrheaGastrointestinal disorders | 1/31 |
| Event | Arm 1 Tolerabilty |
|---|---|
| PruritusSkin and subcutaneous tissue disorders | 17/31 |
| FatigueGeneral disorders | 16/31 |
| CoughRespiratory, thoracic and mediastinal disorders | 14/31 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 11/31 |
| Lung infectionInfections and infestations | 9/31 |
| HypothyroidismEndocrine disorders | 8/31 |
| ConstipationGastrointestinal disorders | 8/31 |
| DiarrheaGastrointestinal disorders | 8/31 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 8/31 |
| Dry skinSkin and subcutaneous tissue disorders | 8/31 |
Demographics for all registered and eligible patients recruited into the STILE study (n=31 patients)
| Age, Continuous(years) | Arm 1 Tolerabilty |
|---|---|
| Median | 73.0 (64.0 to 76.0) |
| Sex: Female, Male(Participants) | Arm 1 Tolerabilty |
|---|---|
| Female | 18 |
| Male | 13 |
| Race (NIH/OMB)(Participants) | Arm 1 Tolerabilty |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 28 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Arm 1 Tolerabilty |
|---|---|
| United Kingdom | 31 |
| Smoking status(Participants) | Arm 1 Tolerabilty |
|---|---|
| Current smoker | 4 |
| Ex-smoker | 25 |
| Never smoker | 2 |
| ECOG Performance Status(Participants) | Arm 1 Tolerabilty |
|---|---|
| ECOG 0 | 7 |
| ECOG 1 | 18 |
| ECOG 2 | 6 |
| Type of NSCLC(Participants) | Arm 1 Tolerabilty |
|---|---|
| Adenocarcinoma | 24 |
| Not Otherwise Specified | 1 |
| Squamous | 5 |
| Stage at diagnosis(Participants) | Arm 1 Tolerabilty |
|---|---|
| IA | 16 |
| IB | 11 |
| IIA | 2 |
| IIB | 1 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2018 to primary completion in Aug 2024, 78 months.
Results were first posted in Jul 2026, 1 year 11 months after primary completion.
Of 123 non-industry phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 107. This study's 78 months is above that.
Counting every sponsor, half of 434 studies reached it within 62 months; a quarter within 41 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab
Carcinoma, Non-Small-Cell Lung →
Royal Marsden NHS Foundation Trust →